Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

945
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
945
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

980
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
980
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

917
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
917
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

741
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
741

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Contemporary medical management of left ventricular assist device patients: integrating sex-specific perspectives.

Current opinion in cardiology·2026
Same author

Yield of Family Screening in Arrhythmogenic Right Ventricular Cardiomyopathy Without a Validated Genetic Cause.

Circulation. Arrhythmia and electrophysiology·2026
Same author

The Role of Buspirone in Antishivering Protocols for Post-Cardiac Arrest Targeted Temperature Management: What Evidence Supports Its Use?

Therapeutic hypothermia and temperature management·2026
Same author

Pregnancy Management and Outcomes with Hypertrophic Cardiomyopathy.

CJC open·2026
Same author

Association of Substance Use and Psychological Conditions With Adverse Pregnancy Outcomes: A Propensity-Matched Analysis.

JACC. Advances·2026
Same author

Cutting-edge nano novel drug delivery carriers (NDCs) for tuberculosis (TB) management: insights into clinical trials and patent landscape.

Journal of microencapsulation·2026
Same journal

Evidence-Based Clinical Recommendations for the Appropriate Use of Diagnostic Tests in Pediatric Allergology: Focus on Asthma, Rhinoconjunctivitis, and Keratoconjunctivitis Vernal.

Journal of clinical medicine·2026
Same journal

Surgical and Transcatheter Approach of a Failed Mitral Valve Repair: A Comprehensive Review on Selecting the Most Suitable Approach.

Journal of clinical medicine·2026
Same journal

Hybrid Metaheuristic Feature Selection for Breast Cancer Detection in Digital Mammography: A Feasibility Study with Nested Validation, Benchmarking, and External Stress Testing.

Journal of clinical medicine·2026
Same journal

Identity Transformation and the Role of Accountability in Recovery from Problematic Pornography Use: A Phenomenological-Hermeneutical Study.

Journal of clinical medicine·2026
Same journal

Does Early Surgical Treatment in Degenerative Cervical Myelopathy Have a Favorable Clinical Outcome and Impact on Quality of Life?

Journal of clinical medicine·2026
Same journal

Shear Wave Elastography in Musculoskeletal Imaging: A Narrative Review.

Journal of clinical medicine·2026
查看所有相关文章

相关实验视频

Updated: Jun 27, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K

导管切除用于通道病变:什么时候少是多?

Adhya Mehta1, Rishi Chandiramani2, Binita Ghosh3

  • 1Department of Internal Medicine, Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY 10461, USA.

Journal of clinical medicine
|April 27, 2024
PubMed
概括
此摘要是机器生成的。

导管切除提供了一个有前途的替代方案,用于管理心室动 (VF) 在通道病变,可能减少心脏突然死亡和改善生活质量. 需要进一步的研究来确认不同通道病症的长期疗效.

关键词:
布鲁加达综合征是什么心脏的剥离是心脏的剥离.道病变 (channelopathies) 是一种通道病变.长时间QT综合征腹腔动脉动 (VF) 是一种心室动.

更多相关视频

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
06:57

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Published on: January 31, 2019

14.7K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.6K

相关实验视频

Last Updated: Jun 27, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
06:57

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Published on: January 31, 2019

14.7K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.6K

科学领域:

  • 心脏病学 心脏病学
  • 电子生理学 电子生理学
  • 遗传学 遗传学 是一个

背景情况:

  • 心室动 (VF) 是患有通道病症的年轻患者心脏突然死亡的重要原因.
  • 目前的治疗方法,如ICD和药物,都有局限性和不良影响.
  • 导管切除正在成为一种潜在的治疗选择.

研究的目的:

  • 审查导管切除在治疗常见通道病变中的作用和有效性.
  • 探索成像和映射方面的进步,以精确识别心律失常触发因素.
  • 了解通道病变中心室节律失常的病理生理学.

主要方法:

  • 对布鲁加达综合征,先天性长QT综合征,短QT综合征和catecholaminergic多形心室动脉动脉动症的导管切除现有文献的综述.
  • 分析成像和绘图技术的进步.
  • 讨论潜在的病理生理学,包括Purkinje网络和心上表皮RVOT角色.

主要成果:

  • 在布鲁加达综合征中导管切除的初步结果是有希望的.
  • 在通道病变中对心律失常的理解得到了改进,突出了特定的解剖区域.
  • 废除的长期疗效和耐用性需要对各种通道病变进行进一步的研究.

结论:

  • 导管切除是一种潜在的治疗策略,用于心室心律失常在通道病变.
  • 进一步的研究是必要的,以确定长期的结果,并将疗效与现有治疗方法进行比较.
  • 由于通道病变的遗传和表型多样性,可能需要个性化的方法.